Overview

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Status:
Completed
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1), compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).
Phase:
Phase 3
Details
Lead Sponsor:
Alnylam Pharmaceuticals